Advertisement

PharmacoEconomics

, Volume 20, Issue 14, pp 943–961 | Cite as

Theoretical Arguments for the Discounting of Health Consequences

Where Do We Go from Here?
  • Angelina LazaroEmail author
Current Opinion

Abstract

Despite the theoretical arguments presented in the literature regarding discounting over the last 25 years, no satisfactory reply has yet been offered to the question of whether health consequences have to be discounted at the same rate as monetary consequences in the economic evaluation of health programmes or interventions designed to improve health. Against this background, the main objective of this paper was to review and systemise these theoretical arguments, with the aim of determining whether any of the positions identified can be accepted without reservation. Having determined that this is not possible, we investigated the rationality of discounting in the literature and, on this basis, propose a potential way to resolve the problem. Thus, we argue that the relationship between the discount of monetary and health consequences has to be determined in an indirect manner, by reference to the relationship maintained by the individual time preference rates for health and money in the context of private and social choice. Although this proposal moves the debate into the empirical field, its advantages must be weighed against the difficulties associated with the estimation of the time preferences.

Keywords

Economic Evaluation Discount Rate Marginal Utility Time Preference Social Discount Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The author gratefully acknowledges the valuable comments made by John Cairns (Health Economics Research Unit, University of Aberdeen, Scotland) and Ramon Barberan (University of Zaragoza, Spain) on an earlier version of this paper. The observations of two anonymous referees have also been of considerable assistance. The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

References

  1. 1.
    Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998; 7 (1): 1–8PubMedCrossRefGoogle Scholar
  2. 2.
    Anders A, Norinder A. Health outcome measures in cost-effectiveness studies: a review of original articles published between 1986 and 1996. Health Policy 1996 51 (2): 87–99Google Scholar
  3. 3.
    Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214–46Google Scholar
  4. 4.
    Smith D, Gravelle H. The practice of discounting economic evaluation of health care intervention. Int J Technol Assess Health Care 2001; 17 (2): 236–43PubMedCrossRefGoogle Scholar
  5. 5.
    Viscusi WK. Discounting health effects for medical decisions. In: Sloan FA, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995: 123–45Google Scholar
  6. 6.
    Johannesson M. Theory and methods of economic evaluation of health care. Dordrecht: Kluwer Academic Publishers, 1996Google Scholar
  7. 7.
    Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296 (13): 716–21PubMedCrossRefGoogle Scholar
  8. 8.
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313 (7052): 275–83PubMedCrossRefGoogle Scholar
  9. 9.
    Russell LB. Is prevention better than cure? Washington DC: The Brookings Institution, 1986Google Scholar
  10. 10.
    World Bank. World development report 1993: investing in health. New York: Oxford University Press, 1993Google Scholar
  11. 11.
    Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 1995Google Scholar
  12. 12.
    Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd ed. Ottawa: CCOHTA, 1997Google Scholar
  13. 13.
    Parsonage M, Neuburger H. Discounting and health benefits. Health Econ 1992; 1: 71–9PubMedCrossRefGoogle Scholar
  14. 14.
    Hillman AL, Kim MS. Economic decision making in healthcare: a standard approach to discounting health outcomes. Pharmacoeconomics 1995; 7 (3): 198–205PubMedCrossRefGoogle Scholar
  15. 15.
    Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? Pharmacoeconomics 1992; 2 (2): 153–62PubMedCrossRefGoogle Scholar
  16. 16.
    Department of Health. Policy appraisal and health. London: Department of Health, 1996Google Scholar
  17. 17.
    Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993; 31 (5): 403–18PubMedCrossRefGoogle Scholar
  18. 18.
    Keeler EB, Cretin S. Discounting of live-saving and other non-monetary effects. Manage Sci 1983; 29 (3): 300–6CrossRefGoogle Scholar
  19. 19.
    Broome J. Discounting the future. Discussion Paper no.: 93/343.Bristol: University of Bristol; 1993Google Scholar
  20. 20.
    Katz DA, Welch HG. Discounting in cost-effectiveness analysis of health care programmes. Pharmacoeconomics 1993; 3 (4): 276–85PubMedCrossRefGoogle Scholar
  21. 21.
    Whittington D, MacRae Jr D. The issue of standing in cost-benefit analysis. J Policy Anal Manage 1986; 5 (4): 665–82CrossRefGoogle Scholar
  22. 22.
    Drummond MF, Ludbrook A, Lowson K, et al. Studies in economic appraisal in health care: vol 2. Oxford: Oxford University Press, 1986Google Scholar
  23. 23.
    Fuchs VR, Zeckhauser R. Valuing health: a “priceless” commodity. Am Econ Rev 1987; 77 (2): 263–8PubMedGoogle Scholar
  24. 24.
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987Google Scholar
  25. 25.
    Hammit JK. Discounting health increments. J Health Econ 1993; 12: 117–20CrossRefGoogle Scholar
  26. 26.
    Grossman M. On the concept of health capital and the demand for health. J Polit Econ 1972; 80 (2): 223–55CrossRefGoogle Scholar
  27. 27.
    Mooney GH. The valuation of human life. London: Macmillan, 1977Google Scholar
  28. 28.
    West RR. Discounting the future: influence of economic model. J Epidemiol Community Health 1996; 50 (3): 239–44PubMedCrossRefGoogle Scholar
  29. 29.
    Parfit D. Reasons and persons. Oxford: Clarendon Press, 1984Google Scholar
  30. 30.
    Welch HG. Comparing apples and oranges: does cost-effectiveness analysis deal fairly with the old and the young? Gerontologist 1991; 31 (3): 332–6PubMedCrossRefGoogle Scholar
  31. 31.
    Broome J. Choice and value in economics. Oxford Economic Papers 1981; 30: 313–33Google Scholar
  32. 32.
    Goodin RE. Discounting discounting. J Public Policy 1982; 2 (1): 53–72CrossRefGoogle Scholar
  33. 33.
    Olsen JA. Time preference for health gains: an empirical investigation. Health Econ 1993; 2: 257–65PubMedCrossRefGoogle Scholar
  34. 34.
    Van Hout BA. Discounting cost and effects: a reconsideration. Health Econ 1998; 7 (7): 581–94PubMedCrossRefGoogle Scholar
  35. 35.
    Redelmeier DA, Heller DN, Weinstein MC. Time preference in medical economics: science or religion? Med Decis Making 1994; 14 (3): 301–3CrossRefGoogle Scholar
  36. 36.
    Ganiats TG. Discounting in cost-effectiveness research. Med Decis Making 1994; 14 (3): 298–300PubMedCrossRefGoogle Scholar
  37. 37.
    Weinstein MC. Estrogen use in postmenopausal women: cost, risks and benefits. N Engl J Med 1980; 303 (6): 308–16PubMedCrossRefGoogle Scholar
  38. 38.
    Weinstein MC. Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 1990; 6 (1): 93–103PubMedCrossRefGoogle Scholar
  39. 39.
    Gravelle H, Smith D. Discounting for health effects in cost benefit and cost effectiveness analysis. Health Econ 2001; 10 (7): 587–99PubMedCrossRefGoogle Scholar
  40. 40.
    Cairns JA. Discounting and health benefits: another perspective. Health Econ 1992; 1: 75–9CrossRefGoogle Scholar
  41. 41.
    Stokey E, Zeckhauser R. A primer for policy analysis. New York: WW Norton, 1978Google Scholar
  42. 42.
    Benzion U, Gafni A. Evaluation of public investment in health care: is the risk irrelevant? J Health Econ 1983; 2: 161–5CrossRefGoogle Scholar
  43. 43.
    Sheldon TA. Discounting in health care decision-making: time for a change? J Public Health Med 1992; 14 (3): 250–6PubMedGoogle Scholar
  44. 44.
    Cairns JA. Health, wealth and time preference. Proj Appraisal 1992; 7 (1): 31–40CrossRefGoogle Scholar
  45. 45.
    Mooney GH. Economics, medicine and health care. London: Harvester Wheatsheaf, 1986Google Scholar
  46. 46.
    Gafni A, Torrance GW. Risk attitude and time preference in health. Manage Sci 1984; 30 (4): 440–51CrossRefGoogle Scholar
  47. 47.
    Mushkin SJ. Health as an investment. J Polit Econ 1962; 70 (2): 129–57CrossRefGoogle Scholar
  48. 48.
    Fisher I. The theory of interest. New York: Macmillan, 1930Google Scholar
  49. 49.
    Feldstein MS. The social time preference discount rate in cost benefit analysis. Econ J 1964; 74: 360–79CrossRefGoogle Scholar
  50. 50.
    Bradford DF. Constraints of government investment opportunities and the choice of discount rate. Am Econ Rev 1975; 65 (5): 887–99Google Scholar
  51. 51.
    Lind RC. Reassessing the government’s discount rate policy in light of new theory and date of a world economy with a degree of capital mobility. J Environ Econ Manage 1990; 18 (2): S8–S28CrossRefGoogle Scholar
  52. 52.
    Robinson JC. Philosophical origins of the social rate of discount in cost-benefit analyses. Milbank Quarterly 1990; 68 (2): 245–65PubMedCrossRefGoogle Scholar
  53. 53.
    Sen AK. On optimizing the rate of saving. Econ J 1961; 71 (283): 479–96CrossRefGoogle Scholar
  54. 54.
    Marglin SA. The social rate of discount and the optimal rate of investment. Q J Econ 1963; 77: 96–111Google Scholar
  55. 55.
    Gyrd-Hansen D, Søgaard J. Discounting life-years: wither time preference? Health Econ 1998; 7 (2): 121–7PubMedCrossRefGoogle Scholar
  56. 56.
    Horowitz JK, Carson RT. Discounting statistical lives. J Risk Uncert 1990; 3: 403–13CrossRefGoogle Scholar
  57. 57.
    Cairns JA. Discounting health benefits. Paper for the 2nd European Conference in Health Economics; 1992 Dec 16–18, ParisGoogle Scholar
  58. 58.
    Chapman GB. Temporal discounting and utility for health and money. J Exp Psychol Learn Mem Cogn 1996; 22 (3): 771–91PubMedCrossRefGoogle Scholar
  59. 59.
    Chapman GB, Coups EJ. Time preferences and preventive health behaviour: acceptance of the influenza vaccine. Med Decis Making 1999; 19 (3): 307–14PubMedCrossRefGoogle Scholar
  60. 60.
    Ganiats TG, Carson RT, Hamm RM, et al. Population-based time preferences for future health outcomes. Med Decis Making 2000; 20: 263–70PubMedCrossRefGoogle Scholar
  61. 61.
    Enemark U, Lyttkens CH, Troeng T, et al. Implicit discount rates of vascular surgeons in the management of abdominal aortic aneurysms. Med Decis Making 1998; 18 (2): 168–77PubMedGoogle Scholar
  62. 62.
    Cairns JA. Valuing future benefits. Health Econ 1994; 3 (4): 221–9PubMedCrossRefGoogle Scholar
  63. 63.
    Cairns JA, Van der Pol MM. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assess 2000; 4 (1): i–iv, 1–83PubMedGoogle Scholar
  64. 64.
    Johannesson M, Johansson P-O. To be or not to be, that is the question: an empirical study of the WTP for an increased life expectancy at an advanced age. J Risk Uncertain 1996; 13: 163–74CrossRefGoogle Scholar
  65. 65.
    Lazaro A, Barberan R, Rubio E. The discounted utility model and social preferences. An analysis of some aletrnative formulations to the conventional discounting. J Econ Psychology 2002; 23 (4): 313–37Google Scholar
  66. 66.
    Chapman GB, Elstein AS. Valuing the future: temporal discounting in health and money. Med Decis Making 1995; 15 (4): 373–86PubMedCrossRefGoogle Scholar
  67. 67.
    Lazaro A, Barberan R, Rubio E. Why discount health more than monetary consequences in the economic evaluation of health care programmes? Appl Econ 2002; 34 (3): 339–50CrossRefGoogle Scholar
  68. 68.
    Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ 2001; 10 (4): 351–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Dpt de Estructura e Historia Económica y Economía Pública, Facultad de DerechoUniversidad de ZaragozaZaragozaSpain

Personalised recommendations